A phase 3 trial evaluated the effects of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis without nasal polyps. The exhalation delivery system with fluticasone ...
Treatment with dupilumab led to significant reductions in sinus opacification, nasal congestion and nasal polyps in patients with allergic fungal rhinosinusitis. Dupilumab, an interleukin-4 receptor ...
Optinose has chalked up a win for its exhalation delivery system in chronic sinusitis patients in a phase 3 clinical trial. Using the system to deliver fluticasone propionate sparked improvements in ...
Approval covers adults and children ≥6 years with prior sinonasal surgery, representing the first FDA-cleared pharmacologic option specifically for AFRS and dupilumab’s ninth U.S. indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results